LAS VEGAS, Sept. 4, 2025 /PRNewswire/ — The Gaucher disease market is primarily being driven by a rising prevalence of the condition and better diagnostic capabilities. Additionally, the expected launch of therapies such as Venglustat (Sanofi), PR001 (Eli Lilly), LY-M001 (Lingyimed),…
